Related references
Note: Only part of the references are listed.Feast or famine in multiple sclerosis therapeutics
Robert J. Fox
LANCET NEUROLOGY (2020)
Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
Ali Manouchehrinia et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Serum neurofilament light as a biomarker in progressive multiple sclerosis
Raju Kapoor et al.
NEUROLOGY (2020)
CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage
Jeppe Romme Christensen et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage
Jeppe Romme Christensen et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle et al.
NEUROLOGY (2019)
Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies
Sarah-Jane Martin et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
Claire Bridel et al.
JAMA NEUROLOGY (2019)
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
Christian Barro et al.
BRAIN (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden
Marco Duering et al.
JOURNAL OF STROKE (2018)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
R. J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Lenka Novakova et al.
NEUROLOGY (2017)
Plasma neurofilament light chain levels in Alzheimer's disease
Wenjun Zhou et al.
NEUROSCIENCE LETTERS (2017)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Robert J. Fox et al.
CONTEMPORARY CLINICAL TRIALS (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Maria Pia Sormani et al.
LANCET NEUROLOGY (2013)
Neurofilaments as biomarkers in multiple sclerosis
Charlotte E. Teunissen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Ibudilast in relapsing-remitting multiple sclerosis A neuroprotectant?
F. Barkhof et al.
NEUROLOGY (2010)
Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease
P. Rolan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)